Neuromyelitis optica (NMO): long-term immunosuppression treatment

Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .

Neuromyelitis optica (NMO): long-term immunosuppression treatment. Antibody positive NMO. Fully referenced neurology checklist.

Indications

  • Antibody positive NMO
  • Optic neuritis (ON) with longitudinally extensive transverse myelitis (LETM)
  • Severe relapsing ON or LETM
  • Absence of MS features on MRI brain
  • Absence of alternative diagnoses

Rituximab: use

Locked: subscribe to see this section.

Rituximab: adverse effects

Locked: subscribe to see this section.

Azathioprine

Locked: subscribe to see this section.

Alternative conventional agents

Locked: subscribe to see this section.

Satralizumab

Locked: subscribe to see this section.

Inebilizumab

Locked: subscribe to see this section.

Other monoclonal antibody agents

Locked: subscribe to see this section.

Investigational agents

Locked: subscribe to see this section.

References

  1. Argyriou AA, Makris N. Neuromyelitis optica: a distinct demyelinating disease of the central nervous system. Acta Neurol Scand 2008; 128:209-217.
  2. Palace J, Leite I, Jacob A. A practical guide to the treatment of neuromyelitis optica. Pract Neurol 2012; 12:209-214.
  3. Scott TF, Frohman EM, De Seze J, Gronseth GS, Weinshenker BG. Evidence-based guideline: clinical exaltation and treatment of transverse myelitis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2011; 77:2128-2134.
  4. Collongues N, de Seze J. An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica. Ther Adv Neurol Disord 2016; 9:180-188.
  5. Sherman E, Han MH. Acute and chronic management of neuromyelitis optica spectrum disorder. Curr Treat Options Neurol 2015; 17:48.
  6. And 44 more. Subscribe to see the full list

Related checklists

Loading...